Victoria Socha

DocwireNews

In patients with type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure as well as the risk for serious adverse renal events; the risk reductions are not seen with other antihyperglycemic therapies. Results of large-scale, randomized, placebo-controlled trials found a 30% to 35% reduction in the risk of hospitalization for heart failure in patients who received SGLT2 compared with those who received placebo.&nbsp; The risk of progression of renal disease, including the occurrence of renal death or the need for dialysis or renal replacement, was 35% to 50% lower in patients in the SGLT2 group compared with those in placebo cohorts.To examine the effects of SGLT2 inhibitors in patients across the spectrum of heart failure, including patients with a markedly reduced ejection fraction, Milton Packer, MD, and colleagues <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022190">reported</a> results of the EMPEROR-Reduced [Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction] study online in the New England Journal of Medicine [10.1056/NEJMoa2022190].The randomized, double-blind, parallel-group, placebo-controlled, event-driven trial was conducted at 520 centers in 20 countries. The primary outcome of interest was a composite of adjudicated cardiovascular death or hospitalization for heart failure, analyzed as the time to the first event. The first secondary outcome was the occurrence of all adjudicated hospitalizations for heart failure, including first and recurrent events. The second secondary outcome was the rate of decline in estimated glomerular filtration rate (eGFR) during double-blind treatment.A total of 7220 patients were screened for eligibility from April 2017 through November 2019. Of those, 3730 met inclusion criteria and were randomly assigned to receive either <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/empagliflozin-linked-with-reduced-mortality-risk-in-diabetics-and-non-diabetics/">empagliflozin</a> (n=1863) or placebo (n=1867). The two groups were similar in baseline characteristics. Half of the overall cohort had a history of diabetes, 73% had a left ventricular ejection fraction of &le;30%, 79% had a N-terminal prohormone of brain natriuretic peptide level of at least 1000 pg per milliliter, 48% had eGFR of &lt;60 mL/min/1.73 m2, and nearly 20% were receiving an angiotensin receptor-neprilysin inhibitor.The primary composite outcome of death from cardiovascular causes or hospitalization for heart failure occurred in 19.4% of the patients in the empagliflozin group (n=361) and in 24.7% of the patients in the placebo group (n=462); hazard ratio (HR), 0.75; 95% confidence interval (CI), 0.65-0.86; P&lt;.001. HRs for the effect of empagliflozin on cardiovascular death and on the first hospitalization for heart failure were 0.92 (95% CI, 0.75-1.12) and 0.69 (95% CI, 0.59-0.81), respectively. The number of patients who would need to have been treated with empagliflozin to prevent one primary event was 19 (95% CI, 13-37).In analyses in prespecified subgroups, the effect of empagliflozin in the primary outcome was consistent, including in patients with diabetes and those without diabetes at baseline. Among patients who were receiving sacubitril-valsartan at baseline, the HR for the comparison between empagliflozin and placebo for the primary outcome was 0.64 (95% CI, 0.45-0.89), compared with 0.77 (95% CI, 0.66-0.90) among patients who were not receiving sacubitril-valsartan.The rate of decline in eGFR over the treatment period was slower in the empagliflozin group compared with the placebo group (&ndash;0.55 mL/min/1.73 m2 per year vs &ndash;2.28 m:/min/1.73 m2 per year). The between-group difference was 1.73 mL/min/1.73 m2 per year (95% CI, 1l10-2.37; P&lt;.001).The risks of serious renal outcomes were lower in the empagliflozin group compared with the placebo group. A composite renal outcome (chronic dialysis or transplantation or a profound, sustained reduction in eGFR) occurred in 1.6% of patients in the empagliflozin group (n=30) and in 3.1% of patients in the placebo group (n=58) (HR, 0.50; 95% CI, 0.32-0.77). In 966 patients with paired measurements prior to study participation and 23 to 45 days following the discontinuation of the trial regimens, enabling assessment of the effects of empagliflozin independent of the presence of the drug, eGFR declined by &ndash;0.93 mL/min/1.73 m2 in the empagliflozin group (95% CI, &ndash;1.97 to 0.11) and by &ndash;4.21 mL/min/1.73 m2 in the placebo group (95% CI, &ndash;5.16 to 3.17).&ldquo;Overall, in this trial, empagliflozin was associated with a lower combined risk of cardiovascular death or hospitalization for heart failure than placebo and with a slower progressive decline in renal function in patients with chronic heart failure and a reduced ejection fraction, regardless of the presence or absence of diabetes,&rdquo; the researchers said.Takeaway Points<ol>
<li>Researchers conducted a study to evaluate the use of empagliflozin in a population of patients with chronic heart failure and a reduced ejection fraction, with and without diabetes.</li>
<li>The trial&rsquo;s secondary outcome was the rate of decline in estimated glomerular filtration rate (eGFR) during the double-blind treatment period. Serious renal outcomes of interest included the need for chronic dialysis or transplantation, or a sustained and profound reduction in eGFR.</li>
<li>Patients in the empagliflozin group had slower annual rate of decline in eGFR compared with those in the placebo group; patients treated with empagliflozin had a lower risk of serious renal outcomes than those who received placebo.</li>
</ol>

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

Renal Outcomes with Empagliflozin Treatment in Patients with Heart Failure

Part of NephTimes Diseases and Conditions

Diabetes and Hypertension

In patients with type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure as well as the risk for serious ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe